09.01.15
Jennifer Panagoulias has been appointed vice president of Regulatory Affairs at Proteon Therapeutics. Ms. Panagoulias will oversee all aspects of regulatory affairs, providing oversight for U.S. and international regulatory matters, including filings and interactions with regulatory authorities.
She joins the company from Alnylam Pharmaceuticals, where she was senior director of Regulatory Affairs. Prior to Alnylam, she held positions of increasing responsibility at Genzyme, rising to global therapeutic head, Regulatory Affairs Neurology following Sanofi's acquisition of Genzyme.
"We are pleased to have Jennifer join our team. Her proven track record in U.S. and international regulatory affairs for global biotechnology franchises will be invaluable to Proteon," said Timothy Noyes, President and Chief Executive Officer. "Jennifer will play a pivotal role in the late stage clinical development and potential regulatory filing and approval of Proteon's lead product candidate, vonapanitase."
She joins the company from Alnylam Pharmaceuticals, where she was senior director of Regulatory Affairs. Prior to Alnylam, she held positions of increasing responsibility at Genzyme, rising to global therapeutic head, Regulatory Affairs Neurology following Sanofi's acquisition of Genzyme.
"We are pleased to have Jennifer join our team. Her proven track record in U.S. and international regulatory affairs for global biotechnology franchises will be invaluable to Proteon," said Timothy Noyes, President and Chief Executive Officer. "Jennifer will play a pivotal role in the late stage clinical development and potential regulatory filing and approval of Proteon's lead product candidate, vonapanitase."